COLORADO
Department of Health Care Policy & Financing

Drug Utilization Review Board
MEETING AGENDA
November 9, 2021
Open Session **1:00 pm - 5:00 pm**

Zoom Link will be posted prior to the meeting at
https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board

Health First Colorado, Colorado's Medicaid program

DUR Board Members	CO-DUR Team
Liza Wilson Claus, PharmD (Chair) Alison Shmerling, MD, MPH (Vice Chair) Miroslav Anguelov, PharmD Todd Brubaker, DO Brian Jackson, MD, MA Shilpa Klocke, PharmD Lyle Laird, PharmD Patricia Lanius, BSPharm, MHA Scott VanEyk, MD	Jeffrey Taylor, PharmD (HCPF) Julia Rawlings, PharmD (CO DUR) Robert L Page II, PharmD, MSPH (CO DUR) Gina Moore, PharmD, MBA (CO DUR) Heather Anderson, PhD (CO DUR) Garth Wright, MPH (CO DUR) Vanessa Patterson, MPH (CO DUR)

1. **Call to Order**
2. **Roll Call and Introductions**
3. **Virtual Meeting Information and General Announcements**
4. **Colorado Department of Health Care Policy and Financing Updates**
5. **Final Approval of Minutes from the August 10, 2021 Meeting**
6. **Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest**
   Presentations:
   - Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist, Jeffrey Taylor, at jeffrey.taylor@state.co.us .
   - Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting.
7. **Clinical Updates and General Orders**
   - FDA New Product & Safety Updates
   - Quarterly Module Summaries
   - Retrospective DUR Reports
   - Quarterly Drug Utilization Reports

COLORADO
Department of Health Care Policy & Financing

8. **New Business** (open for public testimony and DUR Board review)

Proposed Criteria for PDL Drug Classes Scheduled for Review

- Hepatitis C Virus Treatments – Direct-Acting Antivirals (DAAs)
- Human Immunodeficiency Virus Treatments, Oral
  - Single-Ingredient
  - Two-Ingredient
  - Other Combinations
- Pulmonary Arterial Hypertension (PAH) Therapies
  - Phosphodiesterase Inhibitors
  - Endothelin Antagonists
  - Prostanoids
  - Guanylate Cyclase (sGC) Stimulators
- Antidepressants - Newer Generation Agents
- Antiemetics
  - Oral
  - Non-Oral
- H. Pylori Treatments
- Targeted Immune Modulators
- Antibiotics, Inhaled
- Respiratory Agents
  - Inhaled Anticholinergics & Combinations
  - Short-Acting & Long-Acting Beta-Agonists (SABAs & LABAs)
  - Inhaled Corticosteroids & Combinations

Mass review drug classes*

- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  - Oral
  - Non-Oral
- Anti-herpetic Agents
  - Oral
  - Topical
- Fluoroquinolones, Oral
- Hepatitis C Virus Treatments – Ribavirin Products
- Antidepressants
  - Monoamine Oxidase Inhibitors (MAOIs)
  - Tricyclics

COLORADO
Department of Health Care Policy & Financing

Mass review drug classes*, continued

- Triptans and Other Migraine Agents
  - Oral
  - Non-Oral
- Antipsoriatics
  - Oral
  - Topical
- Topical Immunomodulators
- Topical Steroids
  - Low Potency
  - Medium Potency
  - High Potency
  - Very High Potency
- Pancreatic Enzymes
- Proton Pump Inhibitors (PPIs)
- Non-Biologic Ulcerative Colitis Agents
  - Oral
  - Rectal
- Immune Globulins
- Newer Generation Antihistamines
- Antihistamine/Decongestant Combinations
- Intranasal Rhinitis Agents
- Leukotriene Modifiers
- Methotrexate Products
- Epinephrine Products
- Newer Hereditary Angioedema (HAE) Agents
- Antihyperuricemics
- Respiratory Agents – Phosphodiesterase Inhibitors (PDEIs)

* *Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote. Classes designated on the agenda for mass review may be subject to change, and any changes to mass review agenda items will be announced during the meeting.*

COLORADO
Department of Health Care Policy & Financing

9. Proposed Prior Authorization or Utilization Management Criteria for Other Selected Products

- Intravenous Targeted Immune Modulator Products Including:
  - Infliximab products (Remicade and biosimilar product formulations)
  - Enyvio (vedolizumab)
  - Stelara (ustekinumab) IV formulation
  - Actemra (tocilizumab) IV formulation
- Crysvita (burosumab)
- Brexafemme (ibrexafungerp)
- Afinitor Disperz (everolimus) tablet for suspension formulation
- Cystadrops (cysteamine hydrochloride)
- Aemcolo (rifamycin)

10. Adjournment

Next meeting date
February 8, 2022
1:00 pm to 5:00 pm

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.